STOCK TITAN
  1. Home
  2. News
  3. PCRX

Pacira BioSciences Inc - PCRX STOCK NEWS

Welcome to our dedicated news page for Pacira BioSciences (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacira BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacira BioSciences's position in the market.

News
Pacira Appoints Frank D. Lee as Chief Executive Officer
Rhea-AI Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) appoints Frank D. Lee as CEO and member of the Board, effective January 2, 2024. Paul J. Hastings named Chair of the Board. David Stack to remain in advisory role through August 2025. Lee brings more than three decades of global experience in pharmaceutical and biotechnology product development and commercialization. He has a strong track record of leadership success and has held executive positions at Forma Therapeutics, Genentech, Novartis, Janssen, and Eli Lilly. Lee's appointment comes with inducement awards, including a non-qualified stock option and a restricted stock unit award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
management
-
News
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced FDA approval for EXPAREL to be used as an adductor canal block and sciatic nerve block in the popliteal fossa, expanding its reach within lower extremity procedures. The approval was supported by successful Phase 3 studies demonstrating EXPAREL's superiority over bupivacaine in reducing pain scores and opioid consumption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
fda approval
-
News
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in analyst-led fireside chats at two healthcare conferences, providing live audio access and replay options on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
News
Pacira BioSciences Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Pacira BioSciences, Inc. reported financial results for Q3 2023, with total revenues of $163.9 million. Net product sales were $128.7 million for EXPAREL, $28.8 million for ZILRETTA, and $5.3 million for iovera°. The company had a net income of $10.9 million and adjusted EBITDA of $52.9 million. Four new independent directors were appointed to the Board of Directors. Pacira also announced new initiatives to support the American Society of Anesthesiologists. David Stack, the chairman and CEO, will retire.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
earnings
-
News
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
Rhea-AI Summary
Pacira BioSciences, Inc. will report its Q3 financial results on November 2, 2023, followed by a live conference call and webcast. Interested parties can access the event through the Pacira website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
conferences earnings
-
News
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
Rhea-AI Summary
Pacira BioSciences joins ASA's Industry Supporter Program to improve patient care and reduce reliance on opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
News
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
Rhea-AI Summary
Pacira BioSciences announces new appointments to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
management
-
News
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
Rhea-AI Summary
The American Society of Anesthesiologists (ASA) and Pacira BioSciences announced a $2.5 million grant from Pacira to the ASA Charitable Foundation to advance anesthesiology and pain medicine, clinician education, and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
-
News
Pacira BioSciences Announces Leadership Succession Plan
Rhea-AI Summary
Pacira BioSciences CEO David Stack to retire, search for successor initiated
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
none
News
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Pacira BioSciences participates in fireside chat at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
Stock PCRX logo
Pacira BioSciences Inc

Nasdaq:PCRX

PCRX Rankings

#2254 Ranked by Market Cap
#4575 Ranked by Stock Gains
N/A Ranked by Dividends

PCRX Stock Data

1.25B
46.02M
1.21%
108.08%
8.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Parsippany

About PCRX

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.